Previous 10 | Next 10 |
After announcing it had priced an up-sized secondary offering of its shares at $3.50 per share, ADMA Biologics (NASDAQ: ADMA) shares tumbled 13.5% at 12:15 p.m. EST on Friday. A commercial-stage biotech company , ADMA Biologics markets Bivigam and Asceniv, two plasma-derived, polyclonal, i...
ADMA Biologics (NASDAQ: ADMA ) has priced its public offering of 23.5M common shares at $3.50 per share. Underwriters' over-allotment is an additional ~3.5M shares. Closing date is February 11. More news on: ADMA Biologics, Inc., Healthcare stocks news, Stocks on the move, , Read mor...
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bio...
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bio...
Today, we will study why ADMA Biologics ( ADMA ) is a promising biotech player in 2020. Company overview ADMA Biologics is a vertically-integrated biopharmaceutical company focused on developing and commercializing plasma-based therapeutics for the immunocompromised patient population. ...
ADMA Biologics ( ADMA ) recently publicized their preliminary unaudited Q4 and 2019 revenues of $11.9M and $29.2M, respectively. Furthermore, ADMA was nice enough to provide updates on the launches of BIVIGAM and ASCENIV. The market reacted positively to the news with the stock rising from a...
Gainers: Trillium Therapeutics (NASDAQ: TRIL ) +106% . More news on: Trillium Therapeutics Inc., Applied Genetic Technologies Corporation, Genetic Technologies Limited, Stocks on the move, Read more ...
Applied Genetic Technologies (NASDAQ: AGTC ) +53% on positive XLRP data . More news on: Applied Genetic Technologies Corporation, VBI Vaccines Inc., The Peck Company Holdings, Inc., Stocks on the move, Read more ...
ADMA Biologics (NASDAQ: ADMA ) is up 10% premarket on announcing preliminary Q4 and FY 2019 revenues, providing updates on the commercial launches of BIVIGAM and ASCENIV, as well as introducing 2020 strategic outlook. More news on: ADMA Biologics, Inc., Healthcare stocks news...
Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over Fourth Quarter 2018 Full Year 2019 Preliminary Unaudited Total Revenues of $29.2 Million, a 72% Increase Over Full Year 2018 ADMA to Host Conference Call and Webcast in the Firs...
News, Short Squeeze, Breakout and More Instantly...
RAMSEY, N.J. and BOCA RATON, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end ...
RAMSEY, N.J. and BOCA RATON, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announ...
2024-04-26 19:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...